EU Decision Time For Teclistamab & Seven Other Drugs; Incyte Withdraws Parsaclisib Filing

 
• By Neena Brizmohun

Janssen’s bispecific antibody, teclistamab, and Eli Lilly’s potential blockbuster diabetes drug, tirzepatide, are among the products that are this week up for an opinion by the European Medicines Agency on whether they should be approved in the EU.

Question marks background. High resolution 3d render
Companies may soon learn if their drugs will be recommended for EU approval • Source: Alamy

More from Europe

More from Geography